Lightcalls.com
 

Focusing forward what really matter...

Focusing forward what really matters Amid resource constraint issues and aggressive, unrestrained cash-flow targets in 2003, a athletic focus on profitable growth has emerg as a critical direction for corporate Canada. As a proceed companies continue to focus in succession spending restraint to improve their profitability, decrease financial leverage, and prioritize scarce resources.

But given an unprecedent call for capital discipline, companies must now apply abundant greater rigour and scrutiny to their capital investment decisions to faithfully yield success. This extra scrutiny is straited to ensure that all expenditures arc on-strategy and display the right financial characteristics.

Unfortunately, many companies today place little, if any, emphasis in succession risk assessment and quantification. As a spring these companies spend money in succession projects for which:

* The constant financial merit is uncertain;



* The underlying explanation drivers of the business that dictate the economics arc unclear;

* The uncertainty surrounding a given financial valuation and margins of error are not clearly evaluated; and

* The qualitative factors and their impacts to the financial conclusion are not apparent.

The intent of this case-study overview, therefore, is to illustrate to what extent basic risk assessment methods can be applied to capital brew analysis. While this article is based in succession an actual transaction, certain information (including names) has been altered to defend the confidentiality of the parties involved.

Case overview

Thompson Corp. (Thompson) an Alberta-based company, is a well-established IT services provider offering arrangements integration, IT management, and business proces outsourcing services, with vertical expertise primarily in the direction and health sectors.

Although Thompson has a hardy reputation in Western Canada, the company's long-standing accounts are facing mounting attacks from large, global competitors-competitors with the sufficient scale, latitude and capital to offer integrated solutions to customers of all sizes and across many industries. (Margins have become increasingly vulnerable to the competitive pricing strategies adopted at these large players, which include the practices of accepting lower bill-rate work and using fewer subcontractors. Their scale also allows large competitors to use their relative size, track record, and distinctive value-add proposition to gain a larger share of clients' IT wallets, thereby taking market share from small to mid-sized players.) Given Thompson's vulnerability, the company's strategy is to preserve existing accounts with a combination of pricing and service, and to expand its income base through new vertical and market penetration.

The opportunity

Kent Corp. (Kent) a medium-sized financial services company, provides a wide range of financial produces and services-from corporate banking to retail-in Ontario. To lift profitability to a more sustainable footing, Kent is seeking to improve efficiency according to outsourcing its customer billing functions to an IT services company. from one side a registered financial planning proces Kent prefers Thompson as a potential vendor. The opportunity? Thompson would make a significant upfront investment to finance the implementation of a state-of-the-art, customer billing management combination of parts to form a whole and, in return, Kent would chronicle into a long-term customer billing services outsourcing contract with them.

To evaluate the deal's financial merits and to identify focus areas for proper diligence and key deal points for final negotiation, Thompson performs the following analysis:

1) Financial valuation

Below are various financial techniques used in the valuation analysis of the Kent contract.

Note: Relying in succession a single financial metric is a everyday mistake made in capital devise evaluation. While the following financial measurements are each important individually, no undivided approach or technique is through all ages sufficient to support a ye or no decision. Instead, the information derived from these tokens of analyses must be uniteed to determine a deal's overall viability.

a) snare present value (NPV)

The NPV is the instant value of all cash results in the project. By itself, a positive NPV means a deal is accretive to shareholders. However, when there are competing throws with similar NPVs, other financial measuresmust be reviewed in order to determine a deal's overall attractiveness.

Based upon a 15-year discounted cash melt the Kent contract is valued with an NPV of $9M using the Thompson weghted-average-cost-of-capital (WACC) rate of 95%

b) Capital efficiency ratio

This is a ratio of NPV ?· the existing value of capital expenditures to point out the amount of value (or loss) to the company as compared to the amount of capital invested. Essentially, the capital efficiency ratio indicates the snare return per dollar of invested capital. If couple projects generate the same NPV further have different capital efficiency ratios, the common with the higher capital efficiency factor is considered the superior investment. The capital efficiency ratio for the Kent deal is 145%



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.